| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8281ac9f4fb11f15a5da018344453338 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-10 |
| filingDate |
2018-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f58c071786d11e82a765a59a58e6ac0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dce3c4899447f67d96f57f790f950ff1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b79cb8d1a6d96006bc7376b03e4bef1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8238c500bf7671afa11ba9fbbdfcb821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_496a227308e7d0eda0e5ae36bf29ff02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab12bf781fdd9aafb02930d2d08f4f84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0a2ca7768353ab66ad26d9677584b5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e8a3f3873f5921eb9f57df16e0757df |
| publicationDate |
2019-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019177320-A1 |
| titleOfInvention |
Hepatitis b antiviral agents |
| abstract |
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11472808-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10738035-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11377450-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10702528-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10729688-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10723733-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10640511-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10934306-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11198693-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10952978-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11738019-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11058678-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11760755-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10538532-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11596611-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10865211-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11236111-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11236108-B2 |
| priorityDate |
2017-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |